Santhera: Europe's CHMP Issues Positive Opinion For AGAMREE To Treat Duchenne Muscular Dystrophy

Swiss drug maker Santhera Pharmaceuticals Holding AG (SPHDF.OB) announced Friday that European Commission's Committee for Medicinal Products for Human Use or CHMP adopted a positive opinion in favor of approval of AGAMREE (vamorolone) to treat Duchenne muscular dystrophy or DMD patients aged 4 years and older.

Related Keywords

Germany , Switzerland , Swiss , , European Medicines Agency , Catalyst Pharmaceuticals , European Commission , Santhera Pharmaceuticals Holding , More Such Health News , Medicinal Products , Human Use , Prescription Drug User Fee Act , Wmd , Thmp , Duchenne Muscular Dystrophy , Santhera , Vamorolone , Gamre ,